Ketorolac

Ketorolac Tromethamine Tablets / Dispersible Tablets (10mg) is an oral pyrrolizine carboxylic acid NSAID on the WHO Model List framework for short-term continuation therapy following IV ketorolac. It exerts potent analgesic and moderate anti-inflammatory action via cyclooxygenase inhibition. Indicated ONLY as continuation therapy to parenteral ketorolac for moderate-to-severe acute postoperative pain, for a total combined duration not exceeding 5 days.

Ketorolac Tromethamine Injection (30mg/ml) is a parenteral pyrrolo-pyrrole NSAID on the WHO Model List of Essential Medicines. It provides powerful non-opioid analgesia comparable to therapeutic doses of morphine by potently inhibiting COX-1 and COX-2 without causing respiratory depression, sedation, or bowel hypomotility. Indicated for short-term management (up to 5 days only) of moderate-to-severe acute postoperative surgical pain.

Ketorolac Tromethamine Tablets / Dispersible Tablets (10mg) is an oral pyrrolizine carboxylic acid NSAID on the WHO Model List framework for short-term continuation therapy following IV ketorolac. It exerts potent analgesic and moderate anti-inflammatory action via cyclooxygenase inhibition. Indicated ONLY as continuation therapy to parenteral ketorolac for moderate-to-severe acute postoperative pain, for a total combined duration not exceeding 5 days.

Ketorolac Tromethamine Ophthalmic Solution (0.4% w/v) is a topical ocular NSAID on the WHO Model List framework. It inhibits ocular cyclooxygenase to block ocular prostaglandin synthesis, preventing intraoperative miosis and relieving postoperative ocular inflammation and photophobia following cataract surgery and refractive surgery.

Moxifloxacin and NSAID (Bromfenac 0.09% or Ketorolac 0.5%) ophthalmic solution is an antibacterial and non-steroidal anti-inflammatory combination. Moxifloxacin provides broad bactericidal coverage, while the ophthalmic NSAID inhibits cyclooxygenase (COX-1/COX-2) enzymes to block prostaglandin synthesis, relieving ocular pain, photophobia, and anterior chamber flare without the intraocular pressure spikes or cataract risks associated with steroids. Indicated for post-cataract surgery ocular pain, inflammation, and infection prophylaxis.

Olopatadine Hydrochloride (0.1%, 0.2% w/v) is a dual-action mast cell stabilizer and selective histamine H1 receptor antagonist on the WHO Model List of Essential Medicines. It blocks H1 receptors on conjunctival nerves and vascular endothelium (providing rapid relief of itching within 30 minutes) and stabilizes mast cell membranes, inhibiting histamine, tryptase, and leukotriene degranulation. Indicated for the treatment of signs and symptoms of allergic conjunctivitis (seasonal and perennial).